STOCK TITAN

Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Curis, Inc. will release its third quarter 2023 financial results on November 2, 2023. A conference call will be held at 8:30 a.m. ET. Access details provided.
Positive
  • Curis, Inc. will release its third quarter 2023 financial results on November 2, 2023.
Negative
  • None.

LEXINGTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 2, 2023, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

To access the live conference call, please dial (888)-390-0546 from the United States or (416)-764-8688 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies in combination with the BTK inhibitor ibrutinib, and as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-third-quarter-2023-financial-results-and-hold-conference-call-on-november-2-2023-301968409.html

SOURCE Curis, Inc.

FAQ

When will Curis, Inc. release its third quarter 2023 financial results?

Curis, Inc. will release its third quarter 2023 financial results on Thursday, November 2, 2023.

What time is the conference call for Curis, Inc.'s financial results?

The conference call for Curis, Inc.'s financial results will be held at 8:30 a.m. ET on November 2, 2023.

How can I access the live conference call for Curis, Inc.'s financial results?

To access the live conference call, please dial (888)-390-0546 from the United States or (416)-764-8688 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section.

Will there be a replay of the financial results conference call?

Yes, a replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

Curis Inc

NASDAQ:CRIS

CRIS Rankings

CRIS Latest News

CRIS Stock Data

32.95M
7.90M
6.78%
24.37%
2.28%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LEXINGTON